Ivonescimab Phase II shows 64.8% 24-month OS in 1L squamous NSCLC; cash ≥$186M

Summit Therapeutics Inc.

Phase II AK112-201: 24-month OS rate 64.8% in 63 1L squamous NSCLC patients; median OS not reached after 21.0 months follow-up.
In 19 2L+ EGFRm NSCLC patients (post-TKI), median OS 22.5 months; 12-month OS rate 74%.
Near-term catalysts: Chinese NDA decision for AK112-301 (Q2 2024) and interim analysis of AK112-303 vs. pembrolizumab (Q2 2024).
Preliminary cash, cash equivalents, and short-term investments at least $186M as of Dec 31, 2023 (unaudited).
Two global Phase III trials ongoing: HARMONi (EGFRm NSCLC) and HARMONi-3 (1L squamous NSCLC vs. pembrolizumab).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.